Nuvation Bio Completes Thermo Fisher Tech Transfer for IBTROZI Manufacturing
Nuvation Bio completed process technology transfer of IBTROZI to Thermo Fisher Scientific and filed the U.S. manufacturing supplement to its New Drug Application. The company also presented at the Bank of America Global Healthcare Conference 2026, detailing its oncology pipeline and commercial strategy.
1. Thermo Fisher Collaboration
Nuvation Bio finalized the process technology transfer and product introduction of IBTROZI (taletrectinib) to Thermo Fisher Scientific for U.S.-based drug product manufacturing. This transfer supports the filing of an NDA supplement, securing domestic production capacity for advanced ROS1-positive NSCLC patients.
2. Conference Presentation
Nuvation Bio presented at the Bank of America Global Healthcare Conference 2026, reviewing its clinical progress, regulatory milestones and commercialization plans for IBTROZI. Management outlined timelines for drug launch, manufacturing scale-up and late-stage pipeline development.